1. Clinical & Scientific Overview
Metformin Hydrochloride (TIP-MED-000045, Reference Code [4.1]) is classified under
Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04) as a Biguanide; Hepatic Gluconeogenesis Inhibitor & Insulin Sensitiser.
Within the Indian regulatory and compendial framework, it is governed under Schedule G (Medical Supervision Box Warning) & Schedule H (Drugs Rules, 1945).
Glycomet (USV), Okamet (Cipla), Metsmall (Dr. Reddy's), Cetapin (Sanofi)
Immediate-Release (IR) Tablets: 250 mg, 500 mg, 850 mg, 1000 mg; Sustained/Extended-Release (SR/XR) Tablets: 500 mg, 850 mg, 1000 mg; Oral Liquid/Powder Sachets
3. Mechanism of Action & Pharmacodynamics
Activates hepatic AMP-activated protein kinase (AMPK) and inhibits mitochondrial glycerophosphate dehydrogenase (mGPD), suppressing hepatic gluconeogenesis, enhancing peripheral skeletal muscle glucose uptake, and reducing intestinal glucose absorption without stimulating pancreatic beta-cell insulin secretion (minimal intrinsic hypoglycaemia risk).
4. Therapeutic Indications & Evidence-Supported Uses
- First-line pharmacological management of Type 2 Diabetes Mellitus (T2DM)
- Prediabetes metabolic risk reduction and Polycystic Ovary Syndrome (PCOS) insulin resistance (under specialist supervision)
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Reference Summary: Immediate-Release (IR) 500 mg once or twice daily with meals, or Sustained-Release (SR/PR) 500 mg once daily with the evening meal; titrated gradually by 500 mg weekly up to 2000 mg/day (max 2550 mg/day IR) to minimise GI intolerance.
Administration & Meal Timing: Take IR tablets with breakfast and dinner; take once-daily SR/PR tablets with the evening meal. Never crush SR/PR matrix tablets (Handbook Ch 20 Sec 20.6 Do-Not-Crush Matrix p. 209).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Contraindicated in acute or decompensated hepatic insufficiency, severe tissue hypoxia, sepsis, or acute alcohol intoxication (impaired hepatic lactate clearance).
KDIGO 2024 & CDSCO Renal Thresholds: eGFR >= 60 mL/min/1.73m²: Full dose (monitor renal function annually); eGFR 45–59: Continue, monitor every 3–6 months; eGFR 30–44: Halve maximum dose (max 1000 mg/day) and do NOT initiate new therapy; eGFR < 30 mL/min/1.73m²: STRICTLY CONTRAINDICATED due to lactic acidosis risk.
Contraindicated in acute or decompensated hepatic insufficiency, severe tissue hypoxia, sepsis, or acute alcohol intoxication (impaired hepatic lactate clearance).
7. Contraindications, Precautions & High-Risk Warnings
- Severe renal impairment (eGFR < 30 mL/min/1.73 m²)
- Acute metabolic acidosis (including diabetic ketoacidosis or history of metformin-associated lactic acidosis)
- Decompensated heart failure, acute myocardial infarction, sepsis, shock, or severe dehydration
Key Clinical Precautions: Contraindicated in acute or decompensated hepatic insufficiency, severe tissue hypoxia, sepsis, or acute alcohol intoxication (impaired hepatic lactate clearance).
8. Adverse Effects Profile
- Gastrointestinal disturbance: metallic taste, nausea, abdominal cramping, diarrhoea (mitigated by taking WITH meals and switching to SR/PR formulation)
- Vitamin B12 deficiency with long-term therapy (>2–3 years; monitor CBC and serum B12 especially in peripheral neuropathy)
- Rare but potentially fatal Metformin-Associated Lactic Acidosis (MALA: pH < 7.35, lactate > 5 mmol/L)
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Iodinated Intravenous Radiocontrast Media: Hold Metformin prior to or at the time of contrast administration in patients with eGFR 30–60 mL/min/1.73m² or intra-arterial contrast; re-evaluate eGFR at 48 hours before restarting.
- Cationic OCT2/MATE1 Inhibitors (Dolutegravir, Cimetidine, Ranolazine, Trimethoprim): Reduce renal tubular secretion of Metformin; cap Metformin at 1000 mg/day when co-administered with Dolutegravir (TLD regimen).
- Alcohol: Potentiates hyperlactataemia and hypoglycaemia risk.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Swallow tablets WITH or immediately after meals (evening meal for once-daily SR tablets) to prevent stomach upset.
- Do NOT crush, chew, or break Sustained-Release (SR/XR) tablets; note that an inert ghost matrix shell may appear in stool.
- Follow the 'SAD-MANS' Sick-Day Protocol: temporarily pause Metformin during severe vomiting, diarrhoea, high fever, or dehydration and seek medical review.
Storage, Stability & Dispensing Safeguards: Store in moisture-resistant blister packs below 30°C. Verify IR vs SR/PR release modifier and check multi-ingredient FDC strengths (e.g., Glimepiride 1 mg/2 mg + Metformin 500 mg/1000 mg SR).
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) by Tejas Nartam; KDIGO 2024; ICMR T2DM Guidelines; NFI 7th Ed (2026).
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.